7) This was a presentation at the end of May 2026, at the 15th International Biomedical Research into ME Colloquium (BRMEC15).
The full video is available on the Invest in ME website:
6) in ME/CFS they recommend starting with low dose studies. This reduces costs but also side effect and adverse events which can set back trial development for many years. ME/CFS patients are particularly sensitive to medication changes and side effects.
2) They have an interest in GLP-1 RA because it affects biological pathways that come up in the ME/CFS genes they identified such as synaptic and calcium signalling, glucose homeostatis and endothelial dysfunction.
4) Because of the heterogeneity in ME/CFS, different drugs will work for different people - no single trial will benefit everyone. For GLP-1 RA, they recommend focusing on three subgroups: autoimmune/inflammatory, cardiovascular and/or energy metabolism.
